Leading BioSciences Announces National Event Partnership with Sepsis Alliance

Share Article

Leading BioSciences will be the first national Sepsis Challenge sponsor.

Leading BioSciences Logo
We are very excited to have Leading BioSciences on-board this year as one of our national event partners", Tom Heymann, President, Sepsis Alliance

Leading BioSciences, a San Diego-based clinical stage pharmaceutical company, today announced that it has become a national event partner for Sepsis Alliance in 2015.

Sepsis Alliance is the nation's leading patient advocacy organization promoting sepsis awareness. Leading BioSciences focuses on developing treatments designed to slow or completely stop multi-organ failure due to shock. One of its areas of focus is in preventing organ failure resulting from septic shock, which led to this partnership with Sepsis Alliance.

"Sepsis Alliance has established itself as a leader in improving sepsis treatment and sepsis awareness," said Greg Doyle, COO of Leading BioSciences. "Their efforts to raise the visibility of this deadly condition, and their community outreach work inspired us to become a national event partner."

As part of this collaboration, Leading BioSciences will be lead sponsor for the multiple Sepsis Challenge events being held across the country in 2015. In addition, the company will be a "Friend of a Hero" sponsor at the Sepsis Heroes event, taking place in New York City on September 17, 2015.

"We are very excited to have Leading BioSciences on-board this year as one of our national event partners," added Tom Heymann, President and Executive Director of Sepsis Alliance. "They are a vibrant company bringing innovation to the sepsis epidemic, having just received FDA IND clearance to proceed with a Phase 2 clinical trial of their septic shock drug. As an organization dedicated to tackling all aspects of sepsis - from recognition to treatment - we are thrilled with the prospects of a treatment that could save lives of patients with advanced sepsis."

Sepsis, sometimes called blood poisoning by the general public, is a medical emergency that occurs when the body's response to infection begins to injure its own tissues and organs. It is estimated that 258,000 people in the U.S. die every year from sepsis, a preventable condition requiring early diagnosis and rapid treatment.

About Sepsis Alliance

Sepsis Alliance is the leading nonprofit patient advocacy organization in North America promoting awareness of sepsis. Sepsis Alliance's mission is to save lives by raising awareness of sepsis as a medical emergency. The organization hosts national and community events, distributes educational information, and promotes training and education of sepsis and its devastating effects. Sepsis Alliance also provides support by giving patients and family members information about sepsis and Post Sepsis Syndrome, as well as a community forum to share their experiences. Sepsis Alliance, a 501(c)(3) charitable organization, is a GuideStar Gold Rated Charity and a founding member of the Global Sepsis Alliance. For more information, please visit http://www.sepsisalliance.org.

About Leading BioSciences

Leading BioSciences is a clinical-stage, platform pharmaceutical company focused on developing therapies and diagnostics to treat and halt multi-organ failure resulting from shock. Its pipeline includes a drug to treat gastrointestinal breakdown resulting from three common forms of shock: septic shock, cardiogenic shock following heart surgery, and hemorrhagic shock.

Leading BioSciences’ lead product, LB1148, is the result of 10 years of research and testing. LB1148 is an investigational drug formulated to preserve gastrointestinal (GI) integrity during shock and halt multi-organ failure. LB1148 is currently being studied in the SSAIL trial, a multicenter randomized, double-bind, placebo-controlled phase 2 clinical trial evaluating the efficacy and safety of LB1148 for the treatment of septic shock. Participants in the study are randomized to receive LB1148 or placebo for 8 days. The primary endpoint of the SSAIL Trial will assess if LB1148 will decrease the number of days that a patient is alive and requires organ support following septic shock. Additional secondary measures of efficacy will focus on overall mortality, organ function and biomarkers. The SSAIL trial is designed to enroll 250 patients experiencing septic shock at approximately 30 hospitals across the United States and Canada.

Additional information about the SSAIL Trial can be found at http://www.clinicaltrials.gov.

For additional information on Leading Biosciences, please visit http://www.leadingbiosciences.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Greg Doyle
Visit website

Media

Sepsis Alliance Logo